Polyrizon Ltd. - Ordinary Shares (PLRZ)
Healthcare › Surgical & Medical Instruments & Apparatus
Price History
Feb 9, 2026 — Apr 2, 2026Investment Snapshot
- Trading 80% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 3/9 — signs of financial weakness
- Loss-making — negative ROE of -15.9%
Polyrizon Ltd. - Ordinary Shares (PLRZ) is a Healthcare company operating in Surgical & Medical Instruments & Apparatus, listed on the NASDAQ , with a market capitalisation of $20 million . Key value metrics: P/E ratio 25.2, P/B ratio 0.97, Piotroski F-Score 3 out of 9 .
Value Score
Key Metrics
Revenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Polyrizon Ltd. - Ordinary Shares — Fundamental Analysis Summary
Polyrizon Ltd. - Ordinary Shares (PLRZ) is currently trading 80% above its Graham Number of $7.02, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 25.2x.
On financial health, PLRZ shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and negative return on equity of -15.9% (sector average: -19.8%), and minimal leverage with a debt-to-equity ratio of 0.00.
StockPik's composite Value Score for PLRZ is 50/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
PLRZ shows earnings declining at 116%.